|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 May 2001, Vol. 97, No. 10, pp. 3275-3282
RED CELLS
Functional requirements for phenotypic correction of murine
 -thalassemia: implications for human gene therapy
Derek A. Persons,
Esther R. Allay,
Denise E. Sabatino,
Patrick Kelly,
David M. Bodine, and
Arthur W. Nienhuis
From the Division of Experimental Hematology,
Department of Hematology and Oncology, St Jude Children's Research
Hospital, Memphis, TN; and the Hematopoiesis Section, Genetics and
Molecular Biology Branch, National Institutes of Health, Bethesda, MD.
As initial human gene therapy trials for  -thalassemia are
contemplated, 2 critical questions important to trial design and planning have emerged. First, what proportion of genetically corrected hematopoietic stem cells (HSCs) will be needed to achieve a therapeutic benefit? Second, what level of expression of a transferred globin gene
will be required to improve -thalassemic erythropoiesis? These
questions were directly addressed by means of a murine model of
severe -thalassemia. Generation of -thalassemic mice chimeric for
a minority proportion of genetically normal HSCs demonstrated that
normal HSC chimerism levels as low as 10% to 20% resulted in
significant increases in hemoglobin (Hb) level and diminished extramedullary erythropoiesis. A large majority of the peripheral red
cells in these mice were derived from the small minority of normal
HSCs. In a separate set of independent experiments, -thalassemic mice were bred with transgenic mice that expressed different levels of
human globins. Human  -globin messenger RNA (mRNA) expression at 7%
of the level of total endogenous  -globin mRNA in thalassemic erythroid cells resulted in improved red cell morphology, a greater than 2-g/dL increase in Hb, and diminished reticulocytosis and extramedullary erythropoiesis. Furthermore, -globin mRNA expression at 13% resulted in a 3-g/dL increase in Hb and nearly complete correction of red cell morphology and other indices of inefficient erythropoiesis. These data indicate that a significant therapeutic benefit could be achieved with expression of a transferred globin gene
at about 15% of the level of total -globin mRNA in patients with
severe -thalassemia in whom 20% of erythroid precursors express the
vector genome.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Zhao, T. I. Pestina, M. Nasimuzzaman, P. Mehta, P. W. Hargrove, and D. A. Persons
Amelioration of murine {beta}-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both {gamma}-globin and the MGMT drug-resistance gene
Blood,
June 4, 2009;
113(23):
5747 - 5756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-J. Kim, Y.-S. Kim, A. Larochelle, G. Renaud, T. G. Wolfsberg, R. Adler, R. E. Donahue, P. Hematti, B.-K. Hong, J. Roayaei, et al.
Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells
Blood,
May 28, 2009;
113(22):
5434 - 5443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Miccio, R. Cesari, F. Lotti, C. Rossi, F. Sanvito, M. Ponzoni, S. J. E. Routledge, C.-M. Chow, M. N. Antoniou, and G. Ferrari
In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of {beta}-thalassemia
PNAS,
July 29, 2008;
105(30):
10547 - 10552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Nienhuis
Development of gene therapy for blood disorders
Blood,
May 1, 2008;
111(9):
4431 - 4444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Neff, B. C. Beard, and H.-P. Kiem
Survival of the fittest: in vivo selection and stem cell gene therapy
Blood,
March 1, 2006;
107(5):
1751 - 1760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Puthenveetil, J. Scholes, D. Carbonell, N. Qureshi, P. Xia, L. Zeng, S. Li, Y. Yu, A. L Hiti, J.-K. Yee, et al.
Successful correction of the human {beta}-thalassemia major phenotype using a lentiviral vector
Blood,
December 1, 2004;
104(12):
3445 - 3453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hanawa, P. W. Hargrove, S. Kepes, D. K. Srivastava, A. W. Nienhuis, and D. A. Persons
Extended {beta}-globin locus control region elements promote consistent therapeutic expression of a {gamma}-globin lentiviral vector in murine {beta}-thalassemia
Blood,
October 15, 2004;
104(8):
2281 - 2290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Richard, M. Weinreich, K.-H. Chang, J. Ieremia, M. M. Stevenson, and C. A. Blau
Modulating erythrocyte chimerism in a mouse model of pyruvate kinase deficiency
Blood,
June 15, 2004;
103(12):
4432 - 4439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Persons, E. R. Allay, N. Sawai, P. W. Hargrove, T. P. Brent, H. Hanawa, A. W. Nienhuis, and B. P. Sorrentino
Successful treatment of murine {beta}-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells
Blood,
July 15, 2003;
102(2):
506 - 513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Persons, P. W. Hargrove, E. R. Allay, H. Hanawa, and A. W. Nienhuis
The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma -globin gene is influenced by chromosomal position effects and vector copy number
Blood,
March 15, 2003;
101(6):
2175 - 2183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Bharadwaj, C. D. Trainor, P. Pasceri, and J. Ellis
LCR-regulated transgene expression levels depend on the Oct-1 site in the AT-rich region of beta -globin intron-2
Blood,
February 15, 2003;
101(4):
1603 - 1610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Imren, E. Payen, K. A. Westerman, R. Pawliuk, M. E. Fabry, C. J. Eaves, B. Cavilla, L. D. Wadsworth, Y. Beuzard, E. E. Bouhassira, et al.
Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells
PNAS,
October 29, 2002;
99(22):
14380 - 14385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Neff, P. A. Horn, V. E. Valli, A. M. Gown, S. Wardwell, B. L. Wood, C. von Kalle, M. Schmidt, L. J. Peterson, J. C. Morris, et al.
Pharmacologically regulated in vivo selection in a large animal
Blood,
August 28, 2002;
100(6):
2026 - 2031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. May, S. Rivella, A. Chadburn, and M. Sadelain
Successful treatment of murine beta -thalassemia intermedia by transfer of the human beta -globin gene
Blood,
March 15, 2002;
99(6):
1902 - 1908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Gallagher, D. E. Sabatino, D. S. Basseres, D. M. Nilson, C. Wong, A. P. Cline, L. J. Garrett, and D. M. Bodine
Erythrocyte Ankyrin Promoter Mutations Associated with Recessive Hereditary Spherocytosis Cause Significant Abnormalities in Ankyrin Expression
J. Biol. Chem.,
November 2, 2001;
276(45):
41683 - 41689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
